We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Ultra-Specific, Non-Invasive Saliva Test Enables Quantitative Testing Of COVID-19 Antibodies

By LabMedica International staff writers
Posted on 09 Dec 2020
Print article
Illustration
Illustration
A home-collection assay for the quantitative testing of COVID-19 antibodies using saliva now makes it possible for individuals to monitor the level of their COVID-19 antibodies over time without leaving home.

Liquid Diagnostics (San Clemente, CA, USA) has developed and successfully carried out CLIA validation of the test which utilizes the company’s proprietary Amperial technology and measures IgG to the S1 domain of the SARS-CoV-2 spike protein. The Amperial chemistry is based on immobilizing biomolecules in a conducting gel matrix and measuring current following electrochemical detection.

This quantitative COVID-19 antibody test is the first home-collection, ultra-specific, non-invasive saliva test. The test is perfect for monitoring both epidemiologic and vaccine response studies because of its unparalleled specificity of this assay and because individuals can collect samples with an easy-to-use mouth swab at home and mail the sample to a centralized laboratory. Results can be returned the day following the receipt of the sample. Individuals can be tested multiple times to assess the persistence of COVID-19 antibody production following exposure or vaccination.

A CLIA evaluation showed that the test has a specificity (absence of false negatives) of at least 99.994% and a positive predictive value of > 96% (the percentage of positive tests that are true positives). The test is classified as a Laboratory Developed Test. An emergency use authorization (EUA) application has been filed and is awaiting FDA clearance.

"With increasing evidence that the presence of SARS-CoV-2 antibodies correlates with immunity to infection, our Amperial assay with its exquisite specificity and high positive predictive value could be useful for essential workers to determine if they have already had a COVID-19 infection and developed immunity," said Dr. Charles Strom, CEO of Liquid Diagnostics, LLC. "Because it quantifies the amount of antibodies, the test could be used to track the persistence of antibodies following infection or vaccination to assess the potential need for booster shots."

Related Links:
Liquid Diagnostics

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.